![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/a/ad/Zanamivir_structure.svg/640px-Zanamivir_structure.svg.png&w=640&q=50)
Zanamivir
Influenza medication / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Relenza?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Zanamivir is a medication used to treat and prevent influenza caused by influenza A and influenza B viruses. It is a neuraminidase inhibitor and was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B.[3] Zanamivir was the first neuraminidase inhibitor commercially developed. It is marketed by GlaxoSmithKline under the trade name Relenza as a powder for oral inhalation.
Quick Facts Clinical data, Pronunciation ...
![]() | |
Clinical data | |
---|---|
Pronunciation | /zəˈnæmɪvɪər/ |
Trade names | Relenza |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Inhalation, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 2% (oral) |
Protein binding | <10% |
Metabolism | Negligible |
Elimination half-life | 2.5–5.1 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.218.632 ![]() |
Chemical and physical data | |
Formula | C12H20N4O7 |
Molar mass | 332.313 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close